 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...891011121314151617181920» |
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-802;
However, measures should be taken to decrease LTFU of patients. This multi- center cohort is one of the first to show the feasibility and effectiveness of treating chronic HCV patients with SOF/VEL in the primary care setting, in line with the recent AASLD/APASL/EASL/ALEH call to action for HCV elimination.
- Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] Use of sofosbuvir based direct acting antiviral regimens is associated with reduced mortality in liver transplant candidates with hepatitis C (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-798;
In a contemporary national cohort, only a minority of waitlisted HCV positive liver transplant candidates were treated with SOF containing DAAs. However, SOF use was associated with reduced all-cause mortality and increased removal from the waitlist due to improved condition which suggests that HCV treatment should be considered in all HCV infected liver transplant candidates.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-797;
Current DAA regimens, especially if pangenotypic, obtain response rates of at least 95% in a real-life situation. Adding ribavirin to SOF/VEL seems unnecessary in Gt3 patients, regardless of fibrosis.
- voxilaprevir (GS-9857) / Gilead
[VIRTUAL] The outcome of re-treatment of relapsed hepatitis C virus infection after direct acting antiviral treatment failure in resource-limited settings (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-793;
In the absence of resistance testing, Sofosbuvir based combinations remain to be effective and safe alternative treatment regimens for retreating hepatitis C virus-infected patients who experienced previous failure of treatment. Additionally, the choice of the first line of treatment has a significant role in treatment response.
- [VIRTUAL] Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-787;
In this large Italian cohort of GT2 infected pts, the most prevalent subtype was the unusual subtype c. The majority of GT2c failures with recommended regimens did not show specific HCV RAS at failure. Further structural and phenotypic analyses should investigate the role of the common polymorphisms observed in GT2c.
- sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-786;
Although the overall rates of SVR in non-GT3 patients following retreatment with SOF/VEL/VOX are high, we show that in a large cohort of GT3 infected patients retreated with this regimen, SVR was only 81%. This may have important implications for elimination strategies in regions where GT3 dominates.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Improving female street sex worker (FSSW) access to hepatitis C testing and treatment (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-731;
FSSWs have a very high prevalence of HCV PCR positivity but are willing to be treated for HCV if this service is provided outside of a healthcare centre and does not involve venepuncture. Following up this group post treatment to ensure cure and reduce risks of reinfection is also likely to be a challenging despite ongoing support and education in the charity sector.
- tacrolimus / Generic mfg., pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] Kidney transplant from hepatitis C positive donors to hepatitis C negative recipients: report on the first experience in the UK (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-729;
The first cases of transplant of HCV positive donors to HCV negative recipients in the UK are presented. The success of these first cases warrants consideration for wider adoption of this practice in line with UK Position Statement on the use of organs from Hepatitis C viraemic Donors and increased infectious risk donors in Hepatitis C negative recipients
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Prospective multicenter study of sofosbuvir-velpatasvir (SOF/VEL) in hepatitis C virus (HCV) negative liver (LT) and kidney transplant (KT) recipients receiving HCV viremic donors (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-669;
All transmitted infections (22/23) were detectable by day 3, with different viral kinetics in KT versus LT, supporting early initiation of antiviral therapy. Safety was excellent but vigilance of immune-mediated complications is warranted.
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2019 (Channel 5) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-270;
Very high cure rates have been achieved among those who received SVR testing. Challenges remain in identifying and especially linking to care persons living with HCV in Georgia.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] The Clinical Impact of HCV D+/r- Kidney Transplantation (Virtual) - May 29, 2020 - Abstract #ATC2020ATC_1665;
No negative effects of transplantation with HCV+ kidneys were identified in this cohort to date. 2.
- voxilaprevir (GS-9857) / Gilead
[VIRTUAL] Viremic Hepatitis C (HCV) Donors a Viable Option for Lung Transplant Recipients Treated with Real World Delayed Therapy (Virtual) - May 29, 2020 - Abstract #ATC2020ATC_705;
Delayed HCV treatment was successful, tolerated well and it is a practical approach for these complex patients. Still, further careful characterization of this population is needed.
- tacrolimus / Generic mfg.
[VIRTUAL] Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kideney Transplant Recipients (Main Channel) - May 29, 2020 - Abstract #ATC2020ATC_177;
We recently reported that an ultra-short duration (2-4 days peri-operative) DAA prophylaxis using pangenotypic sofosbuvir/velpatasvir (SOF/VEL) in D+/R- KT was able to prevent HCV transmission in a majority (88%) but not all, KT...All pts received standard of care induction rabbit anti-thymocyte globulin followed by triple immunosuppression with tacrolimus, mycophenolate and prednisone... Our data suggests that 7-day DAA prophylaxis is effective in preventing donor-derived HCV transmission and could result in significant cost-savings and increase access to these transplants all over the world.
- || Clinical, Journal: Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. (Pubmed Central) - May 23, 2020
Our data suggests that 7-day DAA prophylaxis is effective in preventing donor-derived HCV transmission and could result in significant cost-savings and increase access to these transplants all over the world. The combination of sofosbuvir, glecaprevir/pibrentasvir and ribavirin could be a rescue therapy after previous relapses on DAA-therapy, especially in patients with relapse after therapy with sofosbuvir, velpatasvir, and voxilaprevir.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] The approach to HCV treatment in patients with haematologic malignancies: an ESGVH-ESGICH cross-sectional survey () - May 22, 2020 - Abstract #ECCMID2020ECCMID_5837;
DAAs prescribers consult few patients with HM, they agree on the need for DAAs treatment but the timing is widely variable. Data on optimal timing and safety of DAAs are urgently needed.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
Trial completion date, Trial primary completion date: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - May 21, 2020
P=N/A, N=500, Enrolling by invitation, Sponsor: Gilead Sciences
Data on optimal timing and safety of DAAs are urgently needed. Trial completion date: Sep 2027 --> Nov 2024 | Trial primary completion date: Sep 2027 --> Nov 2024
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
Clinical, Journal, Real-World Evidence: Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. (Pubmed Central) - May 19, 2020
However, they are contraindicated in patients with decompensated cirrhosis or advanced chronic kidney disease who failed previous DDA-based treatment. Further research is required to customize treatment, to "unpackage" current DAA combinations and to develop generic drugs against HCV.
- | sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: BArT: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection (clinicaltrials.gov) - May 18, 2020
P2, N=40, Active, not recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Further research is required to customize treatment, to "unpackage" current DAA combinations and to develop generic drugs against HCV. Recruiting --> Active, not recruiting
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation. (Pubmed Central) - May 16, 2020
Our study showed excellent efficacy with the safety profile of this drug combination in end-stage renal disease patients. However, larger prospective studies and multicenter randomized controlled trials are needed for further confirmation.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: A Systematic Review (Virtual Meeting Room 6) - May 14, 2020 - Abstract #ISTH2020ISTH_2295;
DAAs increase dabigatran concentration, as predicted from pharmacokinetics. Real world studies are needed to assess clinical relevance of this interaction and describe actual spectrum of possible DDI between DAAs and other DOACs.
- || sofosbuvir/velpatasvir / Generic mfg.
New P1 trial: Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir (clinicaltrials.gov) - May 10, 2020
P1, N=10, Not yet recruiting, Sponsor: Catherine Chappell
- ||| sofosbuvir/velpatasvir / Generic mfg.
Clinical, P3 data, Journal: Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. (Pubmed Central) - May 7, 2020
P3
Real world studies are needed to assess clinical relevance of this interaction and describe actual spectrum of possible DDI between DAAs and other DOACs. Consistent with data from other phase 3 studies, single-tablet sofosbuvir-velpatasvir for 12 weeks is an efficacious and safe treatment for Asian patients with chronic HCV infection, but might have lower efficacy in those infected with HCV genotype 3b and with cirrhosis.
- Daklinza (daclatasvir) / BMS, sofosbuvir/velpatasvir / Generic mfg.
SOFOSBUVIR/ DACLATASVIR AND NOT SOFOSBUVIR/VELPATASVIR RESULTS IN ADVERSE LIPID PROFILE CHANGES IN CHRONIC HEPATITIS C PATIENTS () - May 4, 2020 - Abstract #DDW2020DDW_6355;
Conclusion Our study demonstrated significant increase in HDL, VLDL and cholesterol in sofosbuvir/velpatasvir group. In sofosbuvir/daclatasvir group; all components of lipid profile showed significant increase post treatment.
- CHARACTERIZATION OF PATIENTS WITH CHRONIC HEPATITIS C (C-HCV) ATTENDED AT A HEPATOLOGY CLINIC OF A COMMUNITY HOSPITAL IN NORTH BROOKLYN IN NEW YORK CITY (NYC). () - May 4, 2020 - Abstract #DDW2020DDW_4686;
1) The expansion of screening for C-HCV beyond baby boomers is paramount in its eradication, 2) the suboptimal adherence to appointments may be a reflection of the high risk behaviors that exposed patients to C-HCV. Recommendations: the extension of hepatology services to primary care and behavioral health seem essential to improve access to care and cure of C-HCV
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, sofosbuvir/velpatasvir / Generic mfg.
Journal: Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV. (Pubmed Central) - May 1, 2020
Both progressed to fibrosing cholestatic hepatitis and were successfully retreated with glecaprevir/pibrentasvir for 16 weeks achieving sustained virological response. The higher prevalence of RAS in experience genotype 4 patients and the long time to viral suppression observed in subjects with fibrosing cholestatic hepatitis should be taken into account, considering longer treatment duration to increase the chances of achieving sustained virological response.
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, voxilaprevir (GS-9857) / Gilead
Clinical, Journal: Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. (Pubmed Central) - Apr 30, 2020
The triple combination of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks is the first-line retreatment strategy in patients previously exposed to DAAs. Difficult-to-retreat patients may benefit from the combination of sofosbuvir plus glecaprevir/pibrentasvir and/or the addition of ribavirin and/or longer retreatment duration.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: JSH Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update. (Pubmed Central) - Apr 30, 2020
The new approval of sofosbuvir/velpatasvir prompted us to publish the seventh version of the guidelines in Japanese in March 2019...In 2020, the Committee has decided to publish a new English version, covering general information about treatment for hepatitis C, drugs used, recommended treatments for chronic hepatitis and cirrhosis, and special populations, such as patients who have renal impairment, are on dialysis, or have developed recurrence of hepatitis C after liver transplantation. Furthermore, the Committee has released a separate publication covering the protective effect of antiviral therapy against hepatocarcinogenesis.
- | sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Journal: Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL ) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. (Pubmed Central) - Apr 28, 2020
With the 3CL molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
First Reported Treatment Failure in a Recipient of a Hepatitis C Viremic Heart Transplant () - Apr 26, 2020 - Abstract #ISHLT2020ISHLT_93;
After approval for and treatment with ledipasvir/sofosbuvir (L/S) for 8 weeks, the patient's viral load was initially undetectable...He was subsequently initiated on sofosbuvir/velpatasvir/voxilaprevir (S/V/V) with persistent undetectable viral loads to date at 4 months.SummaryThis is the first documented case of DAA treatment failure in a recipient of HCV+/NAT+ transplanted heart treated with L/S...In the new era of HCV transplantation, selection of DAA and duration of treatment are critical. Awareness of the resistance development data is needed when selecting HCV treatment regimens.
- || Daklinza (daclatasvir) / BMS, sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Real-world Effectiveness of Daclatasvir plus Sofosbuvir and Velpatasvir/Sofosbuvir in Hepatitis C Genotype 2 and 3. (Pubmed Central) - Apr 24, 2020
In genotype 2 and 3 HCV-infected patients, DCV+SOF±RBV and VEL/SOF±RBV produced similar SVR rates within genotype, and regimen did not have a significant impact on odds of SVR. For genotype 3 patients, prior treatment-experience and advanced liver disease were significant predictors of reduced odds of SVR regardless of regimen.
- | sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (clinicaltrials.gov) - Apr 24, 2020
P2, N=20, Recruiting, Sponsor: Baylor Research Institute
For genotype 3 patients, prior treatment-experience and advanced liver disease were significant predictors of reduced odds of SVR regardless of regimen. Trial primary completion date: Mar 2020 --> Jan 2021
- || sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Lung Transplant HCV, Pilot Study (clinicaltrials.gov) - Apr 22, 2020
P1, N=26, Active, not recruiting, Sponsor: University Health Network, Toronto
Trial primary completion date: Mar 2020 --> Jan 2021 Recruiting --> Active, not recruiting | N=20 --> 26 | Trial completion date: Dec 2019 --> Apr 2021 | Trial primary completion date: Oct 2019 --> Jan 2020
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: JSH Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update Protective effect of antiviral therapy against hepatocarcinogenesis. (Pubmed Central) - Apr 17, 2020
The new approval of sofosbuvir/velpatasvir prompted us to publish the seventh version of the guidelines in Japanese in March 2019...In 2020, the Committee has decided to publish a new English version, covering general information about treatment for hepatitis C, drugs used, recommended treatments for chronic hepatitis and cirrhosis, and special populations, such as patients who have renal impairment, are on dialysis, or have developed recurrence of hepatitis C after liver transplantation. Furthermore, the Committee has released a separate publication covering the protective effect of antiviral therapy against hepatocarcinogenesis.
- ||| sofosbuvir/velpatasvir / Generic mfg.
La @US_FDA aprueba el medicamento pediátrico contra la #hepatitisC de @GileadSciences 👉 https://t.co/rIcdNqv6TQ #FDA #Epclusa (Twitter) - Apr 14, 2020
- | sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (clinicaltrials.gov) - Apr 1, 2020
P=N/A, N=450, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Furthermore, the Committee has released a separate publication covering the protective effect of antiviral therapy against hepatocarcinogenesis. Trial primary completion date: Sep 2030 --> Dec 2032
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Trial completion, Trial completion date: Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients (clinicaltrials.gov) - Mar 27, 2020
P1, N=25, Completed, Sponsor: Virginia Commonwealth University
Trial primary completion date: Sep 2030 --> Dec 2032 Active, not recruiting --> Completed | Trial completion date: Apr 2022 --> Mar 2020
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment closed, Enrollment change: SHELTER: Transplanting Hepatitis C Lungs Into Negative Lung Recipients (clinicaltrials.gov) - Mar 25, 2020
P1/2, N=6, Active, not recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | Trial completion date: Apr 2022 --> Mar 2020 Recruiting --> Active, not recruiting | N=10 --> 6
- ||| ponesimod (ACT-128800) / J&J, sofosbuvir+velpatasvir / Generic mfg.
Clinical, NDA: Keeping Track: J&J Submits Ponesimod NDA For MS; US FDA Clears Epclusa For Pediatric HCV https://t.co/0CeyMAYBWs #PinkSheet (Twitter) - Mar 23, 2020
- ||| sofosbuvir+velpatasvir / Generic mfg.
Clinical: Crushed Epclusa... have been using it in transplant recipients and other centers have too. (Twitter) - Mar 9, 2020
- ||| sofosbuvir+velpatasvir / Generic mfg.
Clinical: Mavyret are 3 huge pills taken at once and advertised as once daily. I have had patients who had major issues with this necessitating the use of Epclusa jnstead. (Twitter) - Mar 9, 2020
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] REAL-WORLD EFFECTIVENESS OF HEPATITIS C VIRUS (HCV) TREATMENT WITH DIRECT-ACTING ANTIVIRALS (DAA) IN POPULATIONS WITH FATTY LIVER/NON-ALCOHOLIC STEATOHEPATITIS (FL/NASH), DECOMPENSATED CIRRHOSIS (DCC), HEPATOCELLULAR CARCINOMA (HCC), AND/OR ... () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_2014;
CONCLUSIONS Virologic failures with DAAs in patients with ALD were limited and consistent with reported outcomes in real-world studies of patients with less severe disease. The reduced cure rate in this intent to treat ALD population was predominantly due to patients lost to follow up.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, Daklinza (daclatasvir) / BMS
[VIRTUAL] COST-UTILITY ANALYSIS OF DIRECT ACTING ANTIVIRALS FOR EARLY-STAGE GENOTYPE 1 HCV PATIENTS IN BRAZIL () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1971;
Similar results were observed in all other scenarios. CONCLUSIONS : The present cost-utility analysis shows that GLE+PIB was the most cost-effective treatment, followed by SOF+VEL, whereas sofosbuvir + daclatasvir was considerate the least cost-effective.
- Daklinza (daclatasvir) / BMS
[VIRTUAL] COST-UTILITY ANALYSIS OF NEW ANTIVIRAL TREATMENTS FOR NON-GENOTYPE 1 HEPATITIS C VIRUS IN CHINA- A SOCIETAL PERSPECTIVE () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1929;
As for genotype 3, the combination of sofosbuvir and daclatasvir was the most cost-effective...CONCLUSIONS : For non-genotype 1 hepatitis C patients in China, DAAs are more cost-effective than PR, and they produce better health outcomes and higher quality of life. More importantly, reasonable price reduction of DAAs will increase drug affordability and is of great significance for the global strategy to eliminate viral hepatitis.
- |||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection (clinicaltrials.gov) - Mar 5, 2020
P2, N=217, Completed, Sponsor: Gilead Sciences
More importantly, reasonable price reduction of DAAs will increase drug affordability and is of great significance for the global strategy to eliminate viral hepatitis. Active, not recruiting --> Completed
- ||| sofosbuvir+velpatasvir / Generic mfg.
Reimbursement: For one of the major insurance companies in New York - largely stuck doing Epclusa vs. Mavyret because of this! (Twitter) - Feb 25, 2020
- || sofosbuvir+velpatasvir / Generic mfg.
This was my first time coming across this for Epclusa! (Twitter) - Feb 25, 2020
- Copegus (ribavirin) / Bausch Health, Zubsolv (buprenorphine/naloxone sublingual tablet) / Orexo, Mundipharma, sofosbuvir+velpatasvir / Generic mfg.
Successful Treatment of Hepatitis C by Psychiatrists at an Outpatient Addiction Clinic () - Feb 20, 2020 - Abstract #ASAM2020ASAM_215;
Three subjects had prior unsuccessful HCV treatment with interferon/ribavirin... Our pilot study suggests that uncomplicated HCV infection may be effectively treated by psychiatrists at regularly scheduled visits for buprenorphine/naloxone prescribing and mental health care.
- ||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment change, Trial initiation date: THINKER-NEXT: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (clinicaltrials.gov) - Feb 17, 2020
P2, N=500, Not yet recruiting, Sponsor: University of Pennsylvania
Our pilot study suggests that uncomplicated HCV infection may be effectively treated by psychiatrists at regularly scheduled visits for buprenorphine/naloxone prescribing and mental health care. N=200 --> 500 | Initiation date: Nov 2019 --> Mar 2020
- | ribavirin / Generic mfg.
Enrollment closed: MINMON: Monitoring SOF/VEL in Treatment Na (clinicaltrials.gov) - Feb 5, 2020
P4, N=400, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
N=200 --> 500 | Initiation date: Nov 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (clinicaltrials.gov) - Jan 30, 2020
P=N/A, N=450, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2032 --> Sep 2030